Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase-III study to investigate the safety and efficacy of levodopa/carbidopa (ND0612H) for the treatment of Parkinson's disease.

Trial Profile

A phase-III study to investigate the safety and efficacy of levodopa/carbidopa (ND0612H) for the treatment of Parkinson's disease.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 05 Dec 2016 According to the NeuroDerm media release, Following the discussions with the FDA the Company has decided to discontinue this trial and will replace it with small pharmacokinetic trial for regulatory development.
  • 05 Dec 2016 Status changed from planning to discontinued, according to NeuroDerm media release.
  • 10 Nov 2016 According to a NeuroDerm media release, this trial is expected to initiate at the end of 2016 or beginning of 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top